Cancers of the brain and nervous system account for 1 in every 100 cancer diagnoses in the United States and about 0.3 million diagnoses globally, every year. Surgery, radiotherapy, and chemo-therapy constitute the standard of care. Despite advancements in diagnosis and treatment delivery, mortality rate for these cancers have remained steady for over three decades. Immunotherapy is an emerging fourth treatment modality which has been effective against several cancers but not brain cancers, such as glioblastoma, GBM. Here, we develop in vitro assays to quantify molecular readouts of cell death, cell migration and clonogenicity, and synopsize these as biophysical markers for the rapid evaluation of immune checkpoint inhibitors (ICI), durvalumab and pembrolizumab, alone and in combination with radiotherapy (radioimmunotherapy). We find different trends in their direct action on two GBM cell lines (T98G and U87), even in the absence of immune cells. Radiation alone, and pembrolizumab with radiation, both reduced (p < 0.05) cell-cell adhesion. This reduction suggests increased potential for local invasion. Our assays offer additional insights regarding ICIs, may enable evaluation of their potential efficacy, and could set the stage for pa-tient-specific radioimmunotherapy against brain cancers, engendering improved treatment out-comes.
Glioblastoma (GBM) is the most aggressive and lethal primary brain tumor. The prognosis for patients diagnosed with GBM remains very poor with the median survival time of only 8 months if nothing is done, and 12 - 15 months if surgery, radiotherapy, and chemotherapy are carried out. This therapeutic outcome is abysmal; hence, many new therapeutic modalities are being investigated especially in combination with the standard of care. Nanoparticle-mediated chemo- and radiotherapy are among such new combination modalities. Here, we use a cloud-based, real time live cell imager and an electric cell impedance device to measure cell proliferation/migration in addition to clonogenic assays, following chemotherapy with Temozolomide (TMZ) and radiotherapy, combined with nanoparticles, precisely graphene quantum dots (GQD). Clonogenic assays show statistically significant (p < 0.0001) increase in cell death with radiation, but no statistically significant changes in survival fraction when either GQD, TMZ, or both are added. Surprisingly, we found significant reduction (p < 0.0001) in proliferation/migration, with GQD and TMZ, suggesting new therapeutic targets that may reduce local invasion and reoccurrence. These results provide impetus for cloud-based assays using patient samples, to determine the best course of treatment for GBM, following surgical resection.